Xella Health Secures $3.7M to Revolutionize Women’s Healthcare with AI-Powered Diagnostics
Table of Contents
A new company is poised to disrupt women’s health with a novel approach to diagnostics, securing $3.7 million in pre-seed funding. Xella Health is developing a platform that utilizes menstrual fluid analysis, alongside blood tests and artificial intelligence, to identify the root causes of chronic conditions affecting women.
Historically, the healthcare system has often overlooked the unique biological signals of women, frequently dismissing symptoms as commonplace stress. Xella Health aims to change this paradigm by focusing on previously underutilized biological data: menstrual fluid. This innovative approach promises a more proactive and personalized approach to women’s healthcare.
Decoding Female Biology: A New era of Diagnostics
Xella’s diagnostic platform combines menstrual fluid analysis with peripheral blood testing and multi-omics – an advanced method of studying the interaction between genes, proteins, and metabolites. This comprehensive analysis allows for a depth of insight unavailable through standard clinical practices. The company is targeting conditions like endometriosis, polycystic ovary syndrome (PCOS), and perimenopause, all of which often suffer from delayed or inaccurate diagnoses.
The platform offers insights across three key areas:
- Fertility & reproductive Health: Providing scores for egg quality and quantity, alongside personalized assessments of miscarriage risk.
- Hormonal Milestones: Offering specific staging for perimenopause and tailored guidance for Hormone Replacement Therapy (HRT) personalization.
- Oncology & Longevity: identifying genetic predispositions for reproductive cancers and providing insights into whole-body aging.
“Know Your Code™”: Personalized Care at Scale
Xella’s core mission, encapsulated in the phrase “Know Your Code™,” is to shift women’s health from reactive symptom management to proactive, data-driven foresight. The company’s model integrates three core pillars to achieve this goal: advanced multi-omic diagnostics, longitudinal data tracking biological changes throughout a woman’s life, and clinician-led guidance supported by AI.
“Our mission is to give women the answers and care they have always deserved,” said Kelly Lacob, co-Founder & CEO of Xella. “Xella is building the infrastructure to decode female biology-getting to the root cause of conditions that uniquely, differently or disproportionately affect women, many of which suffer from an unacceptably poor standard of care today.”
The company emphasizes that the AI component is designed to support clinicians, not replace them. Every user will be paired with a dedicated clinician-coach who will translate the complex biological data into actionable health outcomes.
Strong Consumer Demand Signals Successful Launch
Xella Health is already demonstrating meaningful consumer interest,with a 10,000-person waitlist formed ahead of its anticipated launch in Spring 2026. This strong demand underscores a growing appetite for data-driven solutions in women’s health. According to a company release, the pre-seed funding, led by Precursor Ventures, will be used to accelerate product progress and prepare for the platform’s initial rollout.
Xella’s approach represents a significant step towards addressing the long-standing gaps in women’s healthcare, offering the potential for earlier diagnoses, more personalized treatments, and ultimately, improved health outcomes.
Related reading
